Nivolumab plus ipilimumab plus platinum-doublet chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumours have no sensitising EGFR mutation or ALK translocation.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||31/03/2021|
|Rapid review completed||30/04/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that nivolumab in combination with ipilimumab plus platinum-doublet chemotherapy not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.